ENCAPSULATE INC. — National Aeronautics and Space Administration SBIR Phase III: FY25 SBIR PHASE III - NVASIVE: UNRAVELING THE ENIGMA OF METASTASIS
ENCAPSULATE INC. — SBIR Phase III award from National Aeronautics and Space Administration.
Phase III transition / production-path signal
- Phase III work is typically non-SBIR set-aside follow-on. Seeing ENCAPSULATE INC. at Phase III is a strong transition indicator in this domain.
- Competitors studying dual-use scale-up should treat Phase III firms as graduation benchmarks, not just Phase I/II volume leaders.
- At $5,217,527, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Encapsulate Inc. received a $1.23 million NASA SBIR Phase III award for the NVASIVE project. The effort focuses on advancing technology to study and understand how cancer spreads in the body.
- Amount
- $5,217,527
- Agency
- National Aeronautics and Space Administration · National Aeronautics and Space Administration
- Program / Phase
- SBIR · Phase III
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- CT
- Period
- 2025-05-23 → 2028-05-22
Technology domains
Description
FY25 SBIR PHASE III - NVASIVE: UNRAVELING THE ENIGMA OF METASTASIS